Rubicon Research Ltd (RUBICON) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Rubicon Research Ltd on NSE and BSE, with an AI summary of each filing.
Outcome of USFDA Inspection of Rubicon Research Ltd Manufactiring Facility at Ambernath, India
Others (Uncategorized) · 30 Oct 2026, 5:53 am
USFDA Concludes Inspection at Rubicon Research's Ambernath Facility with Five Observations The USFDA conducted an unannounced comprehensive GMP and product-filing inspection at Rubicon Research's Ambernath manufacturing facility from 21st Oct'26 to 29th Oct'26. The regulator issued a Form 483 with five observations: three concerning system improvements and two regarding the product application under review. All observations are procedural with no data integrity issues. Across other sites, R&D units in Canada and Thane hold EIRs with zero observations, New Jersey holds VAI status, while responses have been submitted for Pithampur and Satara inspections.
Intimaiton regarding Q2 Earnings Conference Call.
Intimation · 05 Nov 2026, 5:30 pm
Rubicon Research Schedules 2QFY27 Earnings Conference Call Rubicon Research Limited will host its earnings conference call on 5th Nov'26 at 05:30 PM IST to discuss financial performance for the quarter and half-year ended 30th Sep'26 (2QFY27) alongside future outlook. Senior management participants include CEO Parag Sancheti, CFO Nitin Jajodia, and SVP of Corporate Development & Strategy Sagar Oak. The call will be hosted by Motilal Oswal Financial Services, with primary universal dial-in numbers accessible at +91 22 6280 1149 and +91 22 7115 8050.
Rubicon Research Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve The Un-Audited Standalone ....
Intimation · 05 Nov 2026, 5:30 am
Rubicon Research Board Meeting Scheduled on 5th Nov'26 for Q2 Earnings Rubicon Research Limited has scheduled its Board of Directors meeting for 5th Nov'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities has been closed effective 1st Oct'26 and will reopen 48 hours after the declaration of the financial results.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of the Company''s manufacturing facility in Satara, Maharashtra, India
Others (Uncategorized) · 10 Oct 2026, 1:45 am
Rubicon Research Receives Single Form 483 Observation for Satara Facility The US FDA conducted an unannounced inspection at Rubicon Research’s manufacturing facility in Satara, Maharashtra, from 5th Oct'26 to 9th Oct'26. The audit concluded with the issuance of a Form 483 with one observation, which is procedural and does not involve data integrity. This marks the company's third unannounced US FDA inspection in FY27, following audits at its Toronto R&D site in Apr'26 and Pithampur facility in Jul'26. Rubicon remains confident in resolving the observation with the regulator promptly.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Dislcosure Requirements) Regulatoins 2015, (SEBI Listing Regulations) ESOP alottment
Others (Uncategorized) · 09 Oct 2026, 3:18 am
Rubicon Research Allots 7,200 Equity Shares Under ESOP Scheme 2022 Rubicon Research Limited's Nomination and Remuneration Committee allotted 7,200 fully paid-up equity shares of face value INR 1 each on 8th Oct'26, pursuant to the exercise of options under the Employee Stock Option Scheme 2022. Following this allotment, the company's issued, subscribed, and paid-up equity share capital increased to INR 16,55,39,108, divided into 16,55,39,108 equity shares of INR 1 each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd
Acquisition/ Disposal of Shares · 29 Aug 2026, 4:44 pm
Rubicon Research: Promoter General Atlantic Sells 8.45% Stake Promoter entity General Atlantic Singapore RR Pte Ltd sold 1.40 crore equity shares of Rubicon Research, representing an 8.45% stake. The sale occurred via open market transactions on 25 Aug'26 and 26 Aug'26. Following the disposal, the promoter's shareholding decreased from 35.79% (5.92 crore shares) to 27.34% (4.52 crore shares). This disclosure was made under SEBI's takeover regulations on 28 Aug'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd
Acquisition/ Disposal of Shares · 27 Aug 2026, 2:48 pm
Promoter General Atlantic Sells 8.45% Stake in Rubicon Research Promoter group entity General Atlantic Singapore RR Pte. Ltd. sold 1,40,00,000 shares, representing an 8.45% stake in Rubicon Research. The sale was executed via open market transactions on 25 Aug'26 and 26 Aug'26. Following the disposal, General Atlantic's shareholding in the company decreased from 35.79% (5,92,58,360 shares) to 27.34% (4,52,58,360 shares). This transaction reduces the promoter's holding while increasing the public float for the target company, which is listed on the NSE and BSE.
Voting Results along with the Scrutinizers Report of the 27th Annual General Meeting of the Company, held on Wednesday, 26th August 2026.
Annual General Meeting · 26 Aug 2026, 11:34 pm
Summary of the Proceedings of the 27th Annual General Meeting of the Company.
Annual General Meeting · 26 Aug 2026, 10:18 pm
Trascript of Earnings Call Q1 FY 2026-27
Transcript · 19 Aug 2026, 5:26 pm
Audio Recording of earnings conference call for the quarter ended 30th June, 2026
Audio / Video · 15 Aug 2026, 3:36 am
Rubicon Research Publishes Q1 FY27 Earnings Call Recording Rubicon Research has published the audio recording of its earnings conference call for the quarter ended 30th Jun'26. The filing, dated 14th Aug'26, confirms the call was held on the same day. The recording is available on the company's website, providing investors and analysts with access to management's discussion and outlook for the first quarter of fiscal year 2027. This follows the company's compliance with SEBI's listing regulations.
Monitoring Agency Report for the Quarter ended June 30, 2026.
Others (Uncategorized) · 14 Aug 2026, 10:55 pm
IPO Proceeds Utilization & Timeline Extension for Q1 FY27 Rubicon Research submitted its monitoring agency report for IPO proceeds utilization for the quarter ended 30 Jun'26. Of the INR 5,000 Mn fresh issue, INR 4,169.33 Mn (83.4%) has been utilized, leaving INR 830.67 Mn unutilized. A key utilization was INR 400 Mn towards the acquisition of Arinna Lifesciences. The Board has approved a one-year extension for the utilization timeline to 31 Mar'27. The monitoring agency, India Ratings, noted no deviations from the stated objects of the issue. The unutilized funds are primarily invested in fixed deposits.
Disclosure under Regulation 30 (SEBI LODR) Outcome of Board Meeting
Change in Management · 14 Aug 2026, 10:49 pm
Rubicon Research Announces Key Leadership Changes and Chairman's Extension Rubicon Research has announced a significant leadership transition, effective 14th Aug'26. Mr. Rohit Saraogi, a CA with 24 years of FMCG and B2B experience, has been appointed CFO-Designate and will assume the role of CFO. The current CFO, Mr. Nitin Jajodia, will move to a new operational role as Chief Commercial Officer (CCO) to support the company's growth phase. Additionally, the board has approved the re-appointment and term extension for Chairman Mr. Venkat Changavalli from 18th Sep'26 to 10th Jun'27.
Investor Presentation
Investor Presentation · 14 Aug 2026, 10:37 pm
Rubicon Research Q1FY27: Strong Growth, Margin Expansion, US Acquisition Rubicon Research reported robust Q1FY27 results with revenue at ₹5,343 million (+51.6% YoY) and PAT at ₹848 million (+95.8% YoY). EBITDA margins expanded to 24.6% from 22.6% in Q1FY26. The company recently acquired a USFDA-approved facility in New Jersey for $2.9 million, establishing its first US manufacturing footprint. Management revised its FY27 operating EBITDA margin guidance upward to at least 23%, citing strong revenue visibility and tactical shifts in product mix, while noting the specialty portfolio contributed 36% to Q1 gross profit.
Unaudited Financials Results for Quarter ended June 30, 2026
Outcome · 14 Aug 2026, 10:29 pm
Rubicon Research Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 5,343 (+51.6% YoY | +4.0% QoQ) ■ EBITDA: 1,291 (+63.2% YoY | +8.8% QoQ) ■ EBITDA Margin (%): 24.2 (+172 bps YoY | +107 bps QoQ) ■ PAT: 848 (+95.8% YoY | +10.4% QoQ) ■ EPS (INR): 5.08 (+82.1% YoY | +10.4% QoQ)
Corrigendum to the Integrated Annual Report for the financial year 2025-26
Others (Uncategorized) · 14 Aug 2026, 12:46 am
Notice of 27th Annual General Meeting along with the Intergrated Annual report for FY 2025-26.
Others (Uncategorized) · 11 Aug 2026, 8:04 pm
Earnings Conference Call
Intimation · 14 Aug 2026, 6:00 pm
Rubicon Research to Hold Q1FY27 Earnings Call on 14th August 2026 Rubicon Research has scheduled an earnings conference call on 14th Aug'26 at 6:00 PM IST to discuss its financial performance for the quarter ended 30th Jun'26 (Q1FY27) and the future outlook. Senior management, including CEO Parag Sancheti and CFO Nitin Jajodia, will be present. The call will be led by Tushar Manudhane of Motilal Oswal Financial Services. This event follows the company's formal disclosure to the BSE and NSE exchanges, providing a platform for analysts and investors to engage with leadership.
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve The Un-Audited Standalone ....
Intimation · 14 Aug 2026, 5:30 am
Rubicon Research Board Meeting on Aug 14 to Approve Q1 FY27 Results Rubicon Research has scheduled a Board of Directors meeting for 14 Aug '26 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 30 Jun '26. The trading window for dealing in the company's shares has been closed since 1 Jul '26 and will reopen 48 hours after the results are announced.
Business Responsibility and Sustainabilty Report for the Financial Year 2025-26
Others (Uncategorized) · 04 Aug 2026, 3:23 am
Rubicon Research FY26 Business Responsibility and Sustainability Report Published Rubicon Research has published its Business Responsibility and Sustainability Report for FY26. For FY26, exports contributed 98.44% of total turnover, with all revenue from pharmaceutical products. The company reported a total of 1,303 employees and 582 workers. The permanent employee turnover rate was 19.74%, a decrease from 24.39% in FY25. The company's turnover was ₹13,060.82 million with a net worth of ₹13,209.83 million. There were 18 shareholder complaints filed during the year, all of which were resolved.
Notice of 27th Annual General Meeting along with Integrated Annual Report of the Company for the financial year 2025-26 and Letter for weblink to access Notice and the Integrated Annual Report
Annual General Meeting · 04 Aug 2026, 3:18 am
Newspaper ADvertisement titled "Information Regarding 27th Annual General Meeting to be held through Video Conferencing/Other Audio-Visual Means, Final Dividend and Record Date Intimation
Audio / Video · 30 Jul 2026, 10:17 pm
Communication on tax deduction at source on Dividend
Dividend · 30 Jul 2026, 1:23 am
Rubicon Research Recommends ₹1.50 Dividend for FY26 Rubicon Research's Board has recommended a final dividend of ₹1.50 per share for FY ended Mar'26, subject to shareholder approval at the AGM on 26th Aug'26. The record date is set for 7th Aug'26. The dividend is taxable, with the company deducting tax at source (TDS). The applicable TDS rate is 10% for resident individuals with PAN and 20% for those without. Non-resident shareholders face a 20% TDS rate, plus surcharge/cess, but may avail DTAA benefits upon submitting required documents by 10th Aug'26.